Daiichi Sankyo has dosed the first patient in a phase 1 trial evaluating its AXL inhibitor DS-1205 in combination with gefitinib in patients with metastatic or unresectable epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) who have progressed on therapy with tyrosine kinase inhibitors (TKIs).
Roche’s Kadcyla (trastuzumab emtansine) has significantly reduced the risk of disease recurrence or death compared to Herceptin (trastuzumab) in people with HER2-positive early breast cancer (eBC) in the phase III Katherine study.
MaaT Pharma has dosed first patient in a phase 2 clinical trial of its lead microbiome restoration candidate, MaaT013, in patients with steroid-resistant acute Graft-versus-Host-Disease (SR-aGvHD).
MEI Pharma and BeiGene have entered into a clinical collaboration to evaluate the safety and efficacy of the combination of their respective drugs ME-401, an investigational PI3K delta inhibitor, and zanubrutinib, an investigational BTK inhibitor, for the treatment of patients with B-cell malignancies.
Bristol-Myers Squibb (BMS) and Compugen have agreed to evaluate the safety and tolerability of the combination of Opdivo (nivolumab) and COM701, their respective drugs, for the treatment of patients with advanced solid tumors.
MaxCyte has dosed the first patient in its US phase I dose-escalation clinical trial of chimeric antigen receptor (CAR) therapeutic candidate, MCY-M11.
The Janssen Pharmaceutical Companies of Johnson & Johnson (J&J) has said that single dose of Stelara (ustekinumab) has induced clinical remission and response in adults with moderate to severe ulcerative colitis (UC).
The National Institute for Health Research (NIHR) said that the first clinical trial of a novel approach to modify the progression of Alzheimer’s disease has commenced at the NIHR University College London Hospitals (UCLH) Clinical Research Facility.
Bial and Eisai said that Zebinix (eslicarbazepine acetate) as monotherapy has been confirmed in the Euro-Esli study to be significantly effective than the same drug as adjunctive therapy for focal-onset epilepsy in adults.
UK-based specialty pharma company Diurnal Group said that its adrenal drug Chronocort failed to meet the primary objective of a phase 3 trial in adults with congenital adrenal hyperplasia (CAH).
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.